Incidence rate
(per 100 person-years)		   Hazard ratio
(95% CI)		 P value
NOAC Reference
5 mg apixaban vs warfarin (reference) n = 15,364 n = 15,364
 
    
Stroke/SE* 1.2 1.9
 
 0.61 (0.46-0.81) .001
Major bleeding† 4.0 6.3
 
 0.57 (0.51-0.64) <.001
150 mg dabigatran vs warfarin (reference) n = 5756 n = 5756
 
    
Stroke/SE* 1.3 1.2
 
 1.04 (0.70-1.56) .843
Major bleeding† 3.8 5.0
 
 0.73 (0.56-0.96) .023
20 mg rivaroxaban vs warfarin (reference) n = 17,123 n = 17,123
 
    
Stroke/SE* 1.2 1.6
 
 0.75 (0.62-0.90) .001
Major bleeding† 5.8 5.5
 
 1.04 (0.92-1.17) .549
0.0
0.5
1.0
1.5
2.0
Favors NOACs
Favors warfarin

No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs
versus DOACs.

Appearance of plotted data may be altered when zoom greater than 150% is applied;
refer to values in tables for context when view is zoomed.

1|2|3|4|5